Ngā hua rapu kaituhi

1

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels mā Groenland, Stefanie L., Katz, Daniela, Huitema, Alwin D. R., Steeghs, Neeltje

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
2

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter] mā Hendrikx, Jeroen J M A, Beijnen, Jos H, Huitema, Alwin D R

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
3

Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components mā Bastida, Carla, Soy, Dolors, Ruiz‐Esquide, Virginia, Sanmartí, Raimon, Huitema, Alwin D.R.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
4

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis mā Dorlo, Thomas P. C., Huitema, Alwin D. R., Beijnen, Jos H., de Vries, Peter J.

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
5

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice mā Simeoli, Raffaele, Dorlo, Thomas P. C., Hanff, Lidwien M., Huitema, Alwin D. R., Dreesen, Erwin

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
6

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses mā Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
7

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) mā Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
8

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia mā Boerlage, Thomas C. C., van Hees, Charlotte L. E., Huitema, Alwin D. R., Lauw, Fanny N.

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
9

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing mā Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
10

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes mā van Eijk, Maarten, Boosman, René J., Schinkel, Alfred H., Huitema, Alwin D. R., Beijnen, Jos H.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
11

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS mā de Jong, Karen A.M., Rosing, Hilde, Vermunt, Marit, Huitema, Alwin D.R., Beijnen, Jos H.

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
12

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review mā Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
13

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review mā Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
14

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin mā Zandvliet, Anthe S, Schellens, Jan H M, Dittrich, Christian, Wanders, Jantien, Beijnen, Jos H, Huitema, Alwin D R

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
15

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides mā Derissen, Ellen J. B., Huitema, Alwin D. R., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
16

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model mā ter Heine, Rob, Kane, Sean P., Huitema, Alwin D.R., Krasowski, Matthew D., van Maarseveen, Erik M.

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
17

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs mā Molenaar-Kuijsten, Laura, Van Balen, Dorieke E. M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
18

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa mā Ekhart, Corine, Doodeman, Valerie D, Rodenhuis, Sjoerd, Smits, Paul H M, Beijnen, Jos H, Huitema, Alwin D R

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
19

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents mā Zandvliet, Anthe S., Karlsson, Mats O., Schellens, Jan H. M., Copalu, William, Beijnen, Jos H., Huitema, Alwin D. R.

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
20

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer mā Koolen, Stijn L W, Oostendorp, Roos L, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Huitema, Alwin D R

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels mā Groenland, Stefanie L., Katz, Daniela, Huitema, Alwin D. R., Steeghs, Neeltje

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter] mā Hendrikx, Jeroen J M A, Beijnen, Jos H, Huitema, Alwin D R

Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components mā Bastida, Carla, Soy, Dolors, Ruiz‐Esquide, Virginia, Sanmartí, Raimon, Huitema, Alwin D.R.

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis mā Dorlo, Thomas P. C., Huitema, Alwin D. R., Beijnen, Jos H., de Vries, Peter J.

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice mā Simeoli, Raffaele, Dorlo, Thomas P. C., Hanff, Lidwien M., Huitema, Alwin D. R., Dreesen, Erwin

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses mā Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) mā Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia mā Boerlage, Thomas C. C., van Hees, Charlotte L. E., Huitema, Alwin D. R., Lauw, Fanny N.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing mā Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes mā van Eijk, Maarten, Boosman, René J., Schinkel, Alfred H., Huitema, Alwin D. R., Beijnen, Jos H.

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS mā de Jong, Karen A.M., Rosing, Hilde, Vermunt, Marit, Huitema, Alwin D.R., Beijnen, Jos H.

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review mā Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review mā Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin mā Zandvliet, Anthe S, Schellens, Jan H M, Dittrich, Christian, Wanders, Jantien, Beijnen, Jos H, Huitema, Alwin D R

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides mā Derissen, Ellen J. B., Huitema, Alwin D. R., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model mā ter Heine, Rob, Kane, Sean P., Huitema, Alwin D.R., Krasowski, Matthew D., van Maarseveen, Erik M.

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs mā Molenaar-Kuijsten, Laura, Van Balen, Dorieke E. M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa mā Ekhart, Corine, Doodeman, Valerie D, Rodenhuis, Sjoerd, Smits, Paul H M, Beijnen, Jos H, Huitema, Alwin D R

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents mā Zandvliet, Anthe S., Karlsson, Mats O., Schellens, Jan H. M., Copalu, William, Beijnen, Jos H., Huitema, Alwin D. R.

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer mā Koolen, Stijn L W, Oostendorp, Roos L, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R

Ngā utauta rapu: